プレシジョン・メディシン(精密医療)の世界市場予測

◆英語タイトル:Global Precision Medicine Market – Estimate and Forecast Through (2015–2022)
◆商品コード:MRF61226013
◆発行会社(調査会社):Market Research Future
◆発行日:2016年9月
◆ページ数:85
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(印刷不可)USD4,450 ⇒換算¥507,300見積依頼/購入/質問フォーム
Enterprisewide Price (Global Site License)USD6,250 ⇒換算¥712,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご確認ください。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(支払期限と方法は調整可能、振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はMarket Research Future社の日本における正規販売代理店です。Market Research Future社の概要及び新刊レポートはこちらでご確認いただけます。
【レポートの概要】

Report DescriptionIntroduction
The advancement and innovation of new healthcare technologies are developing the platform for the growth of precision medicine market. Since, the announcement of ‘Precision Medicine Initiative’ by the president Barack Obama in January end, 2015, a large number of research and developments are being done for the development of precise drugs, targeted therapeutics, and laboratory tests. Presently, the main focus of the government initiatives is toward oncology, but it is anticipated to target almost all therapeutic area affected by genetic mutations.
The global precision medicine market is expected to reach $ 88 billion by 2022 at a CAGR of 12.0% during the forecast period.
On the basis of sub-markets, Pharmacogenomics is by far the fastest growing segment of global precision medicine market and it is expected to reach $12.0 billion by 2022.
Based on therapeutics, cancer commands the largest market share of global precision medicine market and it is expected to grow at a CAGR of 11.8% during the period 2015 to 2022.
The Americas dominated the global market in 2014 and accounted for $20.63 billion due to the advancement of gene mapping technologies and increasing precision medicine solutions.
Europe and APAC are estimated to show a high growth by the end of forecast period, where large numbers of developments in precision medicine have been noticed in the last few years are. In addition to this, APAC region is also predicted to grow at the highest CAGR of 14.34% from 2015 to 2022.

Key Players
The leading market players in the global precision medicine market include; Abbott Laboratories (U.S), Almac Group, Ltd. (U.K.), ASURAGEN, Inc. (U.S.), bioMérieux SA (France), Cepheid Inc. (U.S.), GE Healthcare (U.S), GlaxoSmithKline Plc (GSK) (U.K.), Johnson & Johnson (U.S) Medtronic (U.S.) and others.  

STUDY OBJECTIVES OF PRECISION MEDICINE MARKET DEVELOPMENT AND DEMAND FORECAST TO 2022 MARKET
 To provide insights about factors, influencing and affecting the market growth.
 To provide historically and forecast revenue of the market segments and sub-segments with respect to regional markets and their countries.
 To provide historically and forecast revenue of the market segments based on products, and sub-segment for global precision medicine market.
 To provide strategic profiling of key players in the market, comprehensively analyzing their market share, core competencies, and drawing a competitive landscape for the market.
 To provide economic factors that influence the global precision medicine market.

Target Audience
• Pharmaceutical companies
• Research Laboratories
• Hospitals & Clinics
• Service Suppliers
• Potential Investors
• Key executive (CEO and COO) and strategy growth manager

Key Findings
• Americas dominated the global precision medicine market in 2015; however, it is expected to grow at a CAGR of 11.6% during 2015 – 2022.
• The companion diagnostics segment holds the largest share, with $10 billion value of the total market in 2015; while it is expected to reach $21.3 billion in 2022, at a CAGR of 13.4% for the period 2015-2022.
• The cancer segments hold the largest share, with $21.1 billion value, of the total market in 2015; while it is expected to reach $46.3 billion in 2022, at a CAGR of 11.8% for the period 2015 – 2022.
• Abbott Laboratories (U.S), GlaxoSmithKline Plc (GSK) (U.K.), Johnson & Johnson (U.S) Medtronic (U.S.), are so far the leading market players for precision medicine market globally

Regional and Country Analysis of precision medicine Market Development and Demand Forecast to 2022 Market
As per the MRFR analysis, the Americas precision medicine market is poised to reach $49.3 billion by 2022, to grow at a CAGR of around XX% during the forecasted period. The European market was valued at $ 9.2 billion in 2015, and expected to reach at $ 21.9 billion by 2022. Asia-Pacific continues to be the fastest growing region during the forecast period.
The reports also cover country level analysis:
• Americas
o US
o Canada
• South America
o U.S.
• Europe
o Germany
o The U.K.
• Asia-Pacific
o China
o Japan
• Rest of the World (RoW)

【レポートの目次】

Table of Contents

1 REPORT SCOPE 26
1.1 SCOPE OF THE STUDY 26
1.2 PRECISION MEDICINE: REPORT COVERAGE 27
1.3 RESEARCH METHODOLOGY 29
1.3.1 RESEARCH METHODOLOGY FOR THE GLOBAL MARKET STUDY 30
1.3.1.1 Geographical Analysis 30
1.3.1.2 Demand Side & Supply Side Analysis 31
1.3.1.3 Data Synthesis and Bridging 31
1.3.2 GLOBAL PRECISION MEDICINE: RESEARCH METHODOLOGY 32
1.3.3 KEY DATA POINT SOURCES 33
1.3.3.1 Data Points taken from Secondary Sources 33
1.3.3.2 Data Points taken from Primary Sources 33
1.4 REPORT DESCRIPTION 34
2 EXECUTIVE SUMMARY 38
3 MARKET OVERVIEW 42
3.1 INTRODUCTION 42
3.2 MARKET TIMELINE 42
3.3 KEY PARTICIPANTS, STRATEGIES & DEVELOPMENTS 50
3.3.1 GOVERNMENT AGENCIES 50
3.3.2 ACADEMIC INSTITUTIONS 50
3.3.3 DEVICE & SERVICE PROVIDERS 51
3.4 KEY MARKET STRATEGIES AND DEVELOPMENTS 51
3.4.1 INTRODUCTION 51
3.4.2 PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS 52
3.4.3 MERGERS & ACQUISITIONS 54
3.4.4 PRODUCT DEVELOPMENT AND LAUNCH 56
3.4.5 BUSINESS EXPANSION/CONTRACTS 57
3.4.6 PATENTS, APPROVALS AND CERTIFICATIONS 59
3.4.7 OTHERS (EVENTS & RECOGNITIONS) 60
4 MARKET DYNAMICS 61
4.1 INTRODUCTION 61
4.2 MARKET DRIVERS 62
4.2.1 PATIENTS INVOLVEMENT IN PERSONAL HEALTHCARE 62
4.2.2 TECHNOLOGIES DRIVING THE MARKET (E.G. NEXT-GENERATION SEQUENCING TECHNOLOGIES, ULTRA-HIGH THROUGHPUT SEQUENCING) 64
4.2.3 INCREASE IN GENETIC DISEASES 64
4.2.4 POTENTIAL FOR MORE TARGETED THERAPIES 65
4.2.5 INTEGRATION OF BIG DATA HEALTHCARE COMPANIES WITH PHARMA & BIOTECH COMPANIES 65
4.3 MARKET CHALLENGES 66
4.3.1 POTENTIAL THREAT TO PERSONAL DATA 66
4.3.2 HIGH DIAGNOSTIC COST AS A BARRIER 67
4.3.3 POTENTIAL RISK OF HARDWARE OR SOFTWARE FAILURE 68
4.3.4 STRINGENT REGULATIONS AND STANDARDS 68
4.3.5 LACK OF AWARENESS ABOUT THE POSSIBLE APPLICATIONS OF PRECISION MEDICINE 70
4.3.6 REIMBURSEMENT POLICIES AND REGULATORY FRAMEWORK 71
4.3.7 LIMITED KNOWLEDGE ABOUT THE APPLICATION OF TEST AND TECHNIQUES 71
4.3.8 LACK OF RESEARCH AND EVIDENCES CREATING HINDRANCES IN ITS APPLICATION 72
4.4 MARKET OPPORTUNITIES 73
4.4.1 INTRODUCTION OF PRECISION MEDICINE SOLUTIONS IN DEVELOPING ECONOMIES 73
4.4.2 DOWNSIZING THE COST OF GENOME SEQUENCING TO THREE DIGITS 74
5 INDUSTRY DYNAMICS 76
5.1 VALUE CHAIN ANALYSIS 76
5.1.1 DEVICE MANUFACTURER & DRUG PRODUCERS 77
5.1.2 HEALTHCARE PROVIDERS 77
5.1.3 HEALTHCARE ITS OR BIG DATA COMPANIES 77
5.1.4 REGULATORS 77
5.1.5 THIRD PARTY PAYERS 78
5.1.6 PATIENTS 78
5.2 PORTER FIVE FORCE ANALYSIS 78
5.2.1 BARGAINING POWER OF BUYER (PATIENT) 79
5.2.2 BARGAINING POWER OF SUPPLIER 80
5.2.3 THREAT FROM SUBSTITUTE 82
5.2.4 THREAT FROM A NEW ENTRANT 83
5.2.5 INTENSITY OF COMPETITIVE RIVALRY 84
6 CONSORTIUMS, CERTIFICATION, REGULATIONS, AND STANDARDS 85
6.1 INTRODUCTION 85
6.1.1 REGULATORY BODIES 86
6.1.1.1 Food and Drug Administration (FDA) 89
6.1.1.2 Medicines and Healthcare products Regulatory Agency (MHRA) 91
6.1.1.3 Therapeutic Goods Administration (TGA)-Australia 91
6.1.1.4 Conformité Européenne (CE) 92
6.1.2 CONSORTIUMS 92
6.1.3 ALLIANCES/ASSOCIATIONS 94
7 GLOBAL PRECISION MEDICINE MARKET BY ECOSYSTEM PLAYERS 96
7.1 INTRODUCTION 96
7.1.1 MARKET STATISTICS 97
7.2 PHARMACEUTICALS AND BIOTECHNOLOGY COMPANIES 99
7.2.1 KEY MARKET TRENDS, DEVELOPMENTS AND PARTICIPANTS 105
7.2.1.1 Market Trends 105
7.2.1.2 Market Developments 105
7.2.1.3 Key Participants 106
7.3 DIAGNOSTIC COMPANIES 107
7.3.1 KEY MARKET TRENDS, DEVELOPMENTS AND PARTICIPANTS 111
7.3.1.1 Market Trends 111
7.3.1.2 Market Developments 112
7.3.1.3 Key Participants 112
7.4 HEALTHCARE IT SPECIALISTS/ BIG DATA COMPANIES 113
7.4.1 KEY MARKET TRENDS, DEVELOPMENTS AND PARTICIPANTS 119
7.4.1.1 Market Trends 119
7.4.1.2 Market Developments 120
7.4.1.3 Key Participants 121
7.5 CLINICAL LABORATORIES 121
7.5.1 KEY MARKET TRENDS, DEVELOPMENTS AND PARTICIPANTS 125
7.5.1.1 Regulatory bodies and compliances 125
7.5.1.2 Market Trends 126
7.5.1.3 Key Participants 127
8 GLOBAL PRECISION MEDICINE MARKET BY SUB-MARKETS 128
8.1 INTRODUCTION 128
8.1.1 MARKET STATISTICS 129
8.2 COMPANION DIAGNOSTICS 131
8.3 BIOMARKER-BASED TEST 135
8.3.1 ROLE OF BIOBANKING INTO BIOMARKER 137
8.3.2 KEY PARTICIPANTS 141
8.4 TARGETED THERAPEUTICS 142
8.4.1 KEY PARTICIPANTS 144
8.5 PHARMACOGENOMICS (PGX) 144
8.5.1 KEY MARKET TRENDS, DEVELOPMENTS AND PARTICIPANTS 149
8.5.1.1 Market Trends 149
8.5.1.2 Market Developments 150
8.5.1.3 Key Participants 151
8.6 MOLECULAR DIAGNOSTICS 151
8.7 OTHERS 157
8.7.1 NEXT-GENERATION SEQUENCING 159
8.7.2 CONSUMER GENOMICS 159
8.7.2.1 Key Participants 159
8.7.3 3D PRINTING 160
8.7.4 PROSTHETICS MARKET 160
8.7.5 HUMAN TISSUES MARKET 160
9 GLOBAL PRECISION MEDICINE MARKET BY THERAPEUTICS 162
9.1 INTRODUCTION 162
9.1.1 MARKET STATISTICS 163
9.2 CANCER/ONCOLOGY 164
9.2.1 MARKET STATISTICS 165
9.2.2 TYPES OF CANCER 167
9.2.3 DRUGS & TESTS 170
9.2.4 KEY MARKET TRENDS, DEVELOPMENTS & PARTICIPANTS 172
9.2.4.1 Market Trends 172
9.2.4.2 Market Developments 172
9.2.4.3 Key Participants 174
9.3 CARDIOVASCULAR DISEASE (CVD) 175
9.3.1 MARKET STATISTICS 176
9.3.2 DRUGS & TESTS 179
9.3.3 MARKET TRENDS & MARKET DEVELOPMENTS 180
9.3.3.1 Market trend 180
9.3.3.2 Market Developments 181
9.3.3.3 Key Participants 181
9.4 CENTRAL NERVOUS SYSTEM 182
9.4.1 MARKET STATISTICS 182
9.4.2 NEUROLOGICAL 184
9.4.2.1 Neurological Drugs & Tests 185
9.4.3 PSYCHIATRIC DISORDERS 186
9.4.3.1 Psychiatric Disorder Drugs & Tests 186
9.4.4 MARKET TENDS & MARKET DEVELOPMENTS 188
9.4.4.1 Market Trends 188
9.4.4.2 Key Developments 188
9.4.4.3 Key Participants 188
9.5 INFECTIOUS DISEASES 189
9.5.1 MARKET STATISTICS 189
9.5.2 INFECTIOUS DISEASES DRUGS & TESTS 192
9.5.3 MARKET DEVELOPMENTS & PARTICIPANTS 193
9.5.3.1 Key Developments 193
9.5.3.2 Key Participants 194
9.6 OTHERS 194
9.6.1 MARKET STATISTICS 195
9.6.2 MARKET TRENDS, DEVELOPMENTS & PARTICIPANTS 200
9.6.2.1 Market Trends 200
9.6.2.2 Key Developments 200
9.6.2.3 Key Participants 201
10 GLOBAL PRECISION MEDICINE MARKET BY GEOGRAPHY 202
10.1 INTRODUCTION 202
10.1.1 MARKET STATISTICS 203
10.2 THE AMERICAS 204
10.2.1 NORTH AMERICA 207
10.2.1.1 The U.S. 208
10.2.1.2 Canada 209
10.2.1.3 Others 210
10.2.1.4 Key Market Trends, Developments and Participants 210
10.2.1.5 Regulations and Compliances 210
10.2.1.6 Market Trends 210
10.2.1.7 Market Developments 211
10.2.1.8 Key Participants 211
10.2.2 SOUTH AMERICA 212
10.2.2.1 Key Market Trends, Developments and Participants 212
10.2.2.2 Regulations and Compliances 212
10.2.2.3 Market Trends 212
10.2.2.4 Key Participants 212
10.3 EUROPE 213
10.3.1 KEY MARKET TRENDS, DEVELOPMENTS AND PARTICIPANTS 216
10.3.1.1 Regulations and Compliances 216
10.3.1.2 Market Developments 216
10.3.1.3 Key Participants 218
10.4 ASIA-PACIFIC (APAC) 218
10.4.1 KEY MARKET TRENDS, DEVELOPMENTS AND PARTICIPANTS 222
10.4.1.1 Market Developments 222
10.4.1.2 Key Participants 223
10.5 REST OF THE WORLD/MIDDE EAST & AFRICA (MEA) 223
10.5.1 AFRICA 225
10.5.1.1 Middle East 226
10.5.2 KEY MARKET DEVELOPMENTS AND PARTICIPANTS 226
10.5.2.1 Market Developments 226
10.5.2.2 Key Participants 226
11 COMPANY PROFILES 227
11.1 ABBOTT LABORATORIES 227
11.1.1 OVERVIEW 227
11.1.2 FINANCIALS 228
11.1.2.1 Overall Financials 228
11.1.2.2 Financials by Segment 228
11.1.2.3 Financials by Region 229
11.1.2.4 Key Developments 229
11.1.3 SWOT ANALYSIS 231
11.2 ALMAC GROUP, LTD. 232
11.2.1 OVERVIEW 232
11.2.2 FINANCIALS 232
11.2.3 KEY DEVELOPMENTS 233
11.2.4 SWOT ANALYSIS 234
11.3 ASURAGEN, INC. 235
11.3.1 OVERVIEW 235
11.3.2 FINANCIALS 235
11.3.3 KEY DEVELOPMENTS 236
11.3.4 SWOT ANALYSIS 237
11.4 BIOMÉRIEUX SA 238
11.4.1 OVERVIEW 238
11.4.2 FINANCIALS 239
11.4.2.1 Overall Financials 239
11.4.2.2 Financials By Region 239
11.4.2.3 Financials By Segment 240
11.4.3 KEY DEVELOPMENTS 240
11.4.4 SWOT ANALYSIS 242
11.5 CEPHEID INC. 243
11.5.1 OVERVIEW 243
11.5.2 FINANCIALS 244
11.5.2.1 Overall Financials 244
11.5.2.2 Net Revenue By Segment 245
11.5.2.3 Net Revenue By Region 245
11.5.3 KEY DEVELOPMENTS 246
11.5.4 SWOT ANALYSIS 247
11.6 CETICS HEALTHCARE TECHNOLOGIES GMBH 248
11.6.1 OVERVIEW 248
11.6.2 FINANCIALS 248
11.6.3 KEY DEVELOPMENTS 249
11.6.4 SWOT ANALYSIS 250
11.7 GE HEALTHCARE 251
11.7.1 OVERVIEW 251
11.7.2 FINANCIALS 252
11.7.2.1 Overall Financials 252
11.7.2.2 Net Revenue By Segment 253
11.7.2.3 Financial Summary 254
11.7.3 KEY DEVELOPMENTS 254
11.8 GLAXOSMITHKLINE PLC (GSK) 256
11.8.1 OVERVIEW 256
11.8.2 FINANCIALS 257
11.8.2.1 Overall Financials 257
11.8.2.2 Financials By Segment 257
11.8.2.3 Financials By Region 258
11.8.2.4 Financials By Therapeutics 258
11.9 INTOMICS A/S 259
11.9.1 OVERVIEW 259
11.9.2 FINANCIALS 259
11.9.3 KEY DEVELOPMENTS 259
11.9.4 SWOT ANALYSIS 260
11.10 JOHNSON & JOHNSON 261
11.10.1 OVERVIEW 261
11.10.2 FINANCIALS 262
11.10.2.1 Overall Financials 262
11.10.2.2 Net Revenue By Segment 262
11.10.2.3 Net revenue by Region 263
11.10.3 KEY DEVELOPMENTS 263
11.11 LABORATORY CORPORATION OF AMERICA HOLDINGS 264
11.11.1 OVERVIEW 264
11.11.2 FINANCIALS 265
11.11.2.1 Overall Financials 265
11.11.2.2 Financials by Segment 266
11.11.3 KEY DEVELOPMENTS 266
11.11.4 SWOT ANALYSIS 268
11.12 MEDTRONIC 269
11.12.1 OVERVIEW 269
11.12.2 FINANCIALS 270
11.12.2.1 Overall Financials 270
11.12.3 KEY DEVELOPMENTS 270
11.13 NOVARTIS 272
11.13.1 OVERVIEW 272
11.13.2 FINANCIALS 273
11.13.2.1 Overall Financials 273
11.13.2.2 Financials By Region 274
11.13.2.3 Financials By Segment 274
11.14 PFIZER INC. 275
11.14.1 OVERVIEW 275
11.14.2 FINANCIALS 276
11.14.2.1 Overall Financials 276
11.14.2.2 Net Revenue By Segment 276
11.14.2.3 Net Revenue By Region 277
11.14.3 KEY DEVELOPMENTS 277
11.14.4 SWOT ANALYSIS 279
11.15 QIAGEN 280
11.15.1 OVERVIEW 280
11.16 BIOBASE GMBH (SUBSIDIARY) 281
11.16.1 OVERVIEW 281
11.16.2 FINANCIALS 282
11.16.2.1 Overall Financials 282
11.16.3 KEY DEVELOPMENTS (BIOBASE) 283
11.17 QUEST DIAGNOSTICS INC 284
11.17.1 OVERVIEW 284
11.17.2 FINANCIALS 285
11.17.2.1 Overall Financials 285
11.17.2.2 Net Revenue By Segment 286
11.17.3 KEY DEVELOPMENTS 286
11.17.4 SWOT ANALYSIS 288
11.18 RANDOX LABORATORIES LTD. 289
11.18.1 OVERVIEW 289
11.18.2 FINANCIALS 289
11.18.3 KEY DEVELOPMENTS 290
11.18.4 SWOT ANALYSIS 291
11.19 ROCHE HOLDING AG-BR 292
11.19.1 OVERVIEW 292
11.19.2 FINANCIALS 293
11.19.2.1 Overall Financials 293
11.19.2.2 Net Revenue By Segment 293
11.19.3 KEY DEVELOPMENTS 294
11.19.4 SWOT ANALYSIS 295
11.20 SANOFI PHARMA 296
11.20.1 OVERVIEW 296
11.20.2 FINANCIALS 297
11.20.2.1 Overall Financials 297
11.20.2.2 Net Revenue By Segment 297
11.21 TAKEDA PHARMACEUTICAL COMPANY LIMITED 298
11.21.1 OVERVIEW 298
11.21.2 FINANCIALS 299
11.21.2.1 Overall Financials 299
11.21.3 KEY DEVELOPMENTS 299
11.21.4 SWOT ANALYSIS 301
11.22 TEVA PHARMACEUTICAL INDUSTRIES LTD. 302
11.22.1 OVERVIEW 302
11.22.2 FINANCIALS 303
11.22.2.1 Overall Financials 303
11.22.2.2 Net Revenue By Segment 303
11.22.2.3 Net Revenue By Segment 304
11.22.3 KEY DEVELOPMENTS 304
11.22.4 SWOT ANALYSIS 307
11.23 AB-BIOTICS SA 308
11.23.1 OVERVIEW 308
11.24 CARIS LIFE SCIENCES 309
11.24.1 OVERVIEW 309
11.25 HEALTHCORE, INC. 310
11.25.1 OVERVIEW 310
11.26 IBM 311
11.26.1 OVERVIEW 311
11.27 INNVENTIS 312
11.27.1 OVERVIEW 312
11.28 INTEL CORPORATION 313
11.28.1 OVERVIEW 313
11.29 MOLECULAR HEALTH GMBH 314
11.29.1 OVERVIEW 314
11.30 PRECISION FOR MEDICINE 315
11.30.1 OVERVIEW 315

LIST OF TABLES

TABLE 1 LEADING COMPANIES IN THE PRECISION MEDICINE MARKET 37
TABLE 2 DOWNSIZING COST OF GENOME SEQUENCING 74
TABLE 3 FACTORS IMPACTING THE BUYER’S BARGAINING POWER 80
TABLE 4 FACTORS IMPACTING THE SUPPLIER’S BARGAINING POWER 81
TABLE 5 FACTORS IMPACTING THE THREAT FROM SUBSTITUTE 82
TABLE 6 FACTORS IMPACTING THE THREAT FROM NEW ENTRANT 83
TABLE 7 FACTORS IMPACTING THE DEGREE OF COMPETITION 84
TABLE 8 REGULATORY BODIES IN PRECISION MEDICINE MARKET 87
TABLE 9 CONSORTIUMS IN PRECISION MEDICINE MARKET 93
TABLE 10 ALLIANCES/ASSOCIATIONSIN PRECISION MEDICINE MARKET 94
TABLE 11 GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($BILLION) 97
TABLE 12 PHARMA & BIOTECH: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2014-2022 ($BILLION) 100
TABLE 13 PHARMA & BIOTECH: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATION, 2014-2022 ($BILLION) 101
TABLE 14 PHARMA & BIOTECH: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2014-2022 ($BILLION) 102
TABLE 15 KEY DEVELOPMENTS IN PHARMA & BIOTECH COMPANIES(2015) 105
TABLE 16 DIAGNOSTIC TOOLS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2014-2022 ($BILLION) 107
TABLE 17 DIAGNOSTIC TOOLS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATION, 2014-2022 ($BILLION) 108
TABLE 18 DIAGNOSTIC TOOLS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2014-2022 ($BILLION) 109
TABLE 19 KEY DEVELOPMENTS IN DIAGNOSTIC COMPANIES(2015) 112
TABLE 20 HEALTHCARE ITS/BIG DATA: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2014-2022 ($BILLION) 113
TABLE 21 HEALTHCARE ITS/BIG DATA: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATION, 2014-2022 ($BILLION) 114
TABLE 22 HEALTHCARE ITS/BIG DATA: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2014-2022 ($BILLION) 115
TABLE 23 KEY DEVELOPMENTS IN HEALTHCARE IT/BIG DATA COMPANIES(2015) 120
TABLE 24 CLINICAL LABORATORIES: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2014-2022 ($BILLION) 122
TABLE 25 CLINICAL LABORATORIES: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATION, 2014-2022 ($BILLION) 123
TABLE 26 CLINICAL LABORATORIES: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2014-2022 ($BILLION) 124
TABLE 27 GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2014-2022 ($BILLION) 129
TABLE 28 COMPANION DIAGNOSTICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($MILLION) 131
TABLE 29 COMPANION DIAGNOSTICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATION, 2014-2022 ($MILLION) 132
TABLE 30 LIST OF APPROVED COMPANION DIAGNOSTIC DEVICES 133
TABLE 31 BIOMARKER: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($MILLION) 135
TABLE 32 BIOMARKER: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATION, 2014-2022 ($MILLION) 136
TABLE 33 LIST OF BIOBANKS 138
TABLE 34 EXAMPLES OF BIOBANKING INITIATIVES ACROSS SELECTED OECD COUNTRIES 139
TABLE 35 TARGETED THERAPEUTICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($MILLION) 142
TABLE 36 TARGETED THERAPEUTICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATION, 2014-2022 ($MILLION) 143
TABLE 37 PHARMACOGENOMICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($MILLION) 145
TABLE 38 PHARMACOGENOMICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATION, 2014-2022 ($MILLION) 146
TABLE 39 MOLECULAR DIAGNOSTICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($MILLION) 152
TABLE 40 MOLECULAR DIAGNOSTICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATION, 2014-2022 ($MILLION) 153
TABLE 41 OTHER SUB-MARKETS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($MILLION) 157
TABLE 42 OTHER SUB-MARKETS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATION, 2014-2022 ($MILLION) 158
TABLE 43 GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATIONS, 2014-2022 ($BILLION) 163
TABLE 44 CANCER: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($BILLION) 165
TABLE 45 CANCER: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2014-2022 ($BILLION) 166
TABLE 46 CANCER: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2014-2022 ($BILLION) 167
TABLE 47 PRECISION MEDICINE DRUGS AND RELEVANT GENES: ONCOLOGY 170
TABLE 48 PRECISION MEDICINE GENETIC TESTS WITH RESPECT TO ONCOLOGY 171
TABLE 49 KEY DEVELOPMENTS (2013-2015) 172
TABLE 50 CVD: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($BILLION) 176
TABLE 51 CVD: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2014-2022 ($BILLION) 177
TABLE 52 CVD: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2014-2022 ($MILLION) 178
TABLE 53 PRECISION MEDICINE DRUGS AND RELEVANT GENES: CARDIOVASCULAR 179
TABLE 54 PRECISION MEDICINE GENETIC TESTS WITH RESPECT TO CARDIOVASCULAR 180
TABLE 55 KEY DEVELOPMENTS (2014-2015) 181
TABLE 56 CNS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($MILLION) 182
TABLE 57 CNS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2014-2022 ($MILLION) 183
TABLE 58 CNS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2014-2022 ($MILLION) 184
TABLE 59 PRECISION MEDICINE DRUGS AND RELEVANT GENES: NEUROLOGY 185
TABLE 60 PRECISION MEDICINE DRUGS AND RELEVANTGENES: PSYCHIATRIC DISORDERS 186
TABLE 61 PRECISION MEDICINE GENETIC TESTS WITH RESPECT TO PSYCHIATRIC DISORDERS 187
TABLE 62 PSYCHIATRIC DISORDERS: KEY DEVELOPMENTS (2014-2015) 188
TABLE 63 INFECTIOUS DISEASE: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($MILLION) 189
TABLE 64 INFECTIOUS DISEASE: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2014-2022 ($MILLION) 190
TABLE 65 INFECTIOUS DISEASE: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2014-2022 ($MILLION) 191
TABLE 66 PRECISION MEDICINE DRUGS AND RELEVANT GENES: INFECTIOUS DISEASES 192
TABLE 67 OTHER THERAPEUTICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($MILLION) 195
TABLE 68 OTHER THERAPEUTICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY SUB-MARKET TYPES, 2014-2022 ($MILLION) 196
TABLE 69 OTHER THERAPEUTICS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2014-2022 ($MILLION) 197
TABLE 70 PRECISION MEDICINE DRUGS AND RELEVANT GENES: OTHER DISEASES 198
TABLE 71 PRECISION MEDICINE GENETIC TESTS WITH RESPECT TO OTHER DISEASES 199
TABLE 72 GLOBAL PRECISION MEDICINE MARKET VALUE, BY GEOGRAPHY, 2014-2022 ($BILLION) 203
TABLE 73 AMERICAS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($BILLION) 204
TABLE 74 AMERICAS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($BILLION) 205
TABLE 75 AMERICAS: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATIONS, 2014-2022 ($BILLION) 206
TABLE 76 EUROPE: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($BILLION) 213
TABLE 77 EUROPE: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATIONS, 2014-2022 ($BILLION) 214
TABLE 78 APAC: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($BILLION) 219
TABLE 79 APAC: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATIONS, 2014-2022 ($MILLION) 220
TABLE 80 ROW: GLOBAL PRECISION MEDICINE MARKET VALUE, BY ECOSYSTEM PLAYERS, 2014-2022 ($MILLION) 224
TABLE 81 ROW: GLOBAL PRECISION MEDICINE MARKET VALUE, BY THERAPEUTIC APPLICATIONS, 2014-2022 ($MILLION) 225


LIST OF FIGURES

FIGURE 1 PRECISION MEDICINE MARKET STUDY 27
FIGURE 2 RESEARCH METHODOLOGY 29
FIGURE 3 DIFFERENT PHASES OF RESEARCH METHODOLOGY FOR THE GLOBAL MARKET 30
FIGURE 4 PRECISION MEDICINE MARKET: RESEARCH METHODOLOGY 32
FIGURE 5 GLOBAL PRECISION MEDICINE MARKET SHARE, BY ECOSYSTEM, 2014-2022 ($BILLION) 38
FIGURE 6 GLOBAL PRECISION MEDICINE MARKET SIZE, BY SUB-MARKET TYPE, 2014 – 2022 (BILLION) 39
FIGURE 7 GLOBAL PRECISION MEDICINE MARKET SIZE, BY THERPEUTIC APPLICATION, 2014 – 2022 (BILLION) 40
FIGURE 8 GLOBAL PRECISION MEDICINE MARKET SIZE, BY GEOGRAPHY, 2014 – 2022 ($BILLION) 41
FIGURE 9 TIMELINE OF PRECISION MEDICINE 43
FIGURE 10 PRECISION MEDICINE: BENEFITS 45
FIGURE 11 EXAMPLES: APPLIED AREAS OF PRECISION MEDICINE 46
FIGURE 12 ELEMENTS OF PRECISION MEDICINE TECHNOLOGY 47
FIGURE 13 DIFFERENT TYPE OF DATA USED BY BIG DATA COMPANIES 48
FIGURE 14 PRECISION MEDICINE : AREAS OF INTEREST 49
FIGURE 15 PRECISION MEDICINE: PARTNERSHIPS, AGREEMENTS, AND COLLABORATIONS (2015) 53
FIGURE 16 PRECISION MEDICINE : MERGERS & ACQUISITIONS( 2015) 55
FIGURE 17 PRECISION MEDICINE: KEY PRODUCT LAUNCH & DEVELOPMENTS (2015) 57
FIGURE 18 PRECISION MEDICINE: KEY BUSINESS EXPANSIONS & CONTRACTS (2015) 58
FIGURE 19 PRECISION MEDICINE : KEY PATENTS/ APPROVALS ( 2015) 59
FIGURE 20 PRECISION MEDICINE: EVENTS & RECOGNITION (2015) 60
FIGURE 21 MARKET DRIVERS AND CHALLENGES 61
FIGURE 22 BENEFITS OF PRECISION MEDICINE TO PATIENTS 63
FIGURE 23 MAJOR BARRIERS CAUSED BY REGULATION AND STANDARDS 69
FIGURE 24 FLOW CHART OF PRECISION MEDICINE 76
FIGURE 25 PRECISION MEDICINE MARKET: PORTER FIVE FORCE ANALYSIS 79
FIGURE 26 ROLES AND RESPONSIBILITIES OF HEALTHCARE POLICY MAKERS 86
FIGURE 27 ROLE OF FDA IN PRECISION MEDICINE 90
FIGURE 28 CLASSIFICATION OF MEDICAL DEVICES 91
FIGURE 29 GLOBAL PRECISION MEDICINE MARKET BY ECOSYSTEM PLAYERS 98
FIGURE 30 ROLE OF PHARMACEUTICALS AND BIOTECH COMPANIES 103
FIGURE 31 CHALLENGES FACED BY PHARMA & BIOTECH COMPANIES 104
FIGURE 32 DIAGNOSTIC TESTS BENEFITS FOR STAKEHOLDERS 110
FIGURE 33 CHALLENGES FACED BY DIAGNOSTIC COMPANIES 111
FIGURE 34 BENEFITS OF BIG DATA 116
FIGURE 35 TRANSFORMATION OF MEDICINE 117
FIGURE 36 BASIC INGREDIENTS PROVIDED BY BIG DATA FOR PRECISION MEDICINE 118
FIGURE 37 CHALLENGES FACED BY BIG DATA COMPANIES 119
FIGURE 38 OECD RECOMMENDATIONS ON THE GOVERNANCE OF CLINICAL TRIALS 126
FIGURE 39 TYPES OF PRECISION MEDICINE SUB-MARKET 130
FIGURE 40 BENEFITS OF COMPANION DIAGNOSTICS 133
FIGURE 41 FUNCTION OF BIOMARKERS 137
FIGURE 42 BIOBANKS SERVICES 141
FIGURE 43 DEVELOPMENT IN PGX 147
FIGURE 44 MODEL SYSTEMS USED IN PGX 148
FIGURE 45 CHALLENGES OF PGX STUDIES 149
FIGURE 46 FIGURE TITLE MISSING 154
FIGURE 47 MOLECULAR DIAGNOSTICS: APPLICATION 155
FIGURE 48 MOLECULAR DIAGNOSTICS: BENEFITS 156
FIGURE 49 GLOBAL PRECISION MEDICINE MARKET: BY THERAPEUTICS 164
FIGURE 50 TARGET SCOPE OF PRECISION MEDICINE BY CANCER TYPES 169
FIGURE 51 GLOBAL PRECISION MEDICINE MARKET CLASSIFICATION, BY GEOGRAPHY 202
FIGURE 52 KEY DRIVERS FOR PRECISION MEDICINE: NORTH AMERICA 207
FIGURE 53 OBJECTIVES OF THE PRECISION MEDICINE INITIATIVE 209
FIGURE 54 APAC: MARKET CHALLENGES 221
FIGURE 55 ABBOTT: OVERALL FINANCIALS ($BILLION), 2012-2014 228
FIGURE 56 ABBOTT: NET REVENUE BY SEGMENTS ($BILLION), 2012-2014 228
FIGURE 57 ABBOTT: NET REVENUE BY REGION, 2012-2014 ($BILLION) 229
FIGURE 58 ABBOTT: SWOT ANALYSIS 231
FIGURE 59 ALMAC: SWOT ANALYSIS 234
FIGURE 60 ASURAGEN: SWOT ANALYSIS 237
FIGURE 61 BIOMERIEUX: OVERALL FINANCIALS ($MILLION), 2012-2014 239
FIGURE 62 BIOMERIEUX: NET REVENUE BY REGION, 2014 239
FIGURE 63 BIOMERIEUX: NET REVENUE BY SEGMENT, 2014 240
FIGURE 64 BIOMERIEUX: SWOT ANALYSIS 242
FIGURE 65 CEPHEID: OVERALL FINANCIALS, 2012-2014 ($MILLION) 244
FIGURE 66 CEPHEID: NET REVENUE, BY SEGMENTS, 2012-2014 ($MILLION) 245
FIGURE 67 CEPHEID: NET REVENUE, BY REGION, 2012-2014 ($MILLION) 245
FIGURE 68 CEPHEID: SWOT ANALYSIS 247
FIGURE 69 CETICS HEALTHCARE: SWOT ANALYSIS 250
FIGURE 70 GE CORPORATION: OVERALL FINANCIALS, 2012-2014 ($BILLION) 252
FIGURE 71 GE CORPORATION: NET REVENUE, BY SEGMENTS, 2012-2014 ($MILLION) 253
FIGURE 72 GE CORPORATION: HEALTHCARE SEGMENT, 2014 253
FIGURE 73 GSK: OVERALL FINANCIALS, 2012-2014 ($BILLION) 257
FIGURE 74 GSK: NET REVENUE BY SEGMENT, 2014 ($BILLION) 257
FIGURE 75 GSK: NET REVENUE BY REGION, 2014 ($BILLION) 258
FIGURE 76 GSK: NET REVENUE BY THERAPEUTICS, 2014 ($BILLION) 258
FIGURE 77 INTOMICS: SWOT ANALYSIS 260
FIGURE 78 J&J: OVERALL FINANCIALS, 2012 - 2014 ($BILLION) 262
FIGURE 79 J&J: NET REVENUE BY SEGMENT, 2012 - 2014 ($MILLION) 262
FIGURE 80 J&J: NET REVENUE BY REGION, 2012 - 2014 ($MILLION) 263
FIGURE 81 LABCORP: OVERALL FINANCIALS ($MILLION), 2012-2014 265
FIGURE 82 NET REVENUE BY SEGMENTS, 2012-2014 ($MILLION) 266
FIGURE 83 LABCORP: SWOT ANALYSIS 268
FIGURE 84 MEDTRONIC: OVERALL FINANCIALS, 2012 - 2014 ($MILLION) 270
FIGURE 85 NOVARTIS: OVERALL FINANCIALS, 2012 - 2014 ($BILLION) 273
FIGURE 86 NOVARTIS: NET REVENUE BY REGION, 2014 ($BILLION) 274
FIGURE 87 NOVARTIS: NET REVENUE BY SEGMENT, 2014 ($BILLION) 274
FIGURE 88 PFIZER: OVERALL FINANCIALS, 2012 – 2014 ($BILLION) 276
FIGURE 89 PFIZER: NET REVENUE, BY SEGMENT, 2012-2014 ($MILLION) 276
FIGURE 90 PFIZER: NET REVENUE, BY REGION, 2012-2014 ($BILLION) 277
FIGURE 91 PFIZER: SWOT ANALYSIS 279
FIGURE 92 QIAGEN: OVERALL FINANCIALS ($MILLION), 2012-2014 282
FIGURE 93 QIAGEN: NET REVENUE BY REGION ($MILLION), 2014 282
FIGURE 94 QIAGEN: NET REVENUE BY SEGMENT, 2014 283
FIGURE 95 QUEST: OVERALL FINANCIALS, 2012 - 2014 ($MILLION) 285
FIGURE 96 QUEST: NET REVENUE, BY SEGMENT, 2012 - 2014 ($MILLION) 286
FIGURE 97 QUEST: SWOT ANALYSIS 288
FIGURE 98 RANDOX: SWOT ANALYSIS 291
FIGURE 99 ROCHE: OVERALL FINANCIALS, 2012-2014 ($BILLION) 293
FIGURE 100 ROCHE: NET REVENUE, BY SEGMENTS, 2012-2014 ($BILLION) 293
FIGURE 101 ROCHE: SWOT ANALYSIS 295
FIGURE 102 SANOFI PHARMA: OVERALL FINANCIALS, 2012-2014($BILLION) 297
FIGURE 103 SANOFI PHARMA: NET REVENUE, BY SEGMENTS, 2012-2014 ($BILION) 297
FIGURE 104 TAKEDA: OVERALL FINANCIALS, 2012-2014 ($BILLION) 299
FIGURE 105 TAKEDA: SWOT ANALYSIS 301
FIGURE 106 TEVA: OVERALL FINANCIALS, 2012 – 2014 ($BILLION) 303
FIGURE 107 TEVA: NET REVENUE SHARE, BY SEGMENT (2014) 303
FIGURE 108 TEVA: NET REVENUE SHARE, BY REGION (2014) 304
FIGURE 109 TEVA: SWOT ANALYSIS 307


【掲載企業】

Abbott Laboratories (U.S), Almac Group, Ltd. (U.K.), ASURAGEN, Inc. (U.S.), bioMérieux SA (France), Cepheid Inc. (U.S.), GE Healthcare (U.S), GlaxoSmithKline Plc (GSK) (U.K.), Johnson & Johnson (U.S) Medtronic (U.S.) and others.

【レポートのキーワード】

プレシジョン・メディシン、精密医療

★調査レポート[プレシジョン・メディシン(精密医療)の世界市場予測]販売に関する免責事項
★調査レポート[プレシジョン・メディシン(精密医療)の世界市場予測]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆